The outpost against cancer:universal cancer only markers  

作　　者：Chengchen Qian Xiaolong Zou Wei Li Yinshan Li Wenqiang Yu 

机构地区：[1]Shanghai Epiprobe Biotechnology Co.,Ltd,Shanghai 200233,China [2]Department of General Surgery,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China [3]Shandong Epiprobe Medical Laboratory Co.,Ltd,Heze 274108,China [4]People's Hospital of Ningxia Hui Autonomous Region,Ningxia Medical University,Yinchuan 750002,China [5]Shanghai Public Health Clinical Center&Department of General Surgery,Huashan Hospital&Cancer Metastasis Institute&Laboratory of RNA Epigenetics,Institutes of Biomedical Sciences,Shanghai Medical College,Fudan University,Shanghai 200032,China

出　　处：《Cancer Biology & Medicine》2023年第11期806-815,共10页癌症生物学与医学（英文版）

基　　金：supported by the National Key R&D Program of China(Grant No.2022BEG01003);the National Natural Science Foundation of China(Grant Nos.32270645 and 32000505);a Grant from Heilongjiang Provincial Health Commission(Grant No.2020-111);a Grant from Heze Science and Technology Institute(Grant No.2021KJPT07)。

摘　　要：Cancer is the leading cause of death worldwide.Early detection of cancer can lower the mortality of all types of cancer;however,effective early-detection biomarkers are lacking for most types of cancers.DNA methylation has always been a major target of interest because DNA methylation usually occurs before other detectable genetic changes.While investigating the common features of cancer using a novel guide positioning sequencing for DNA methylation,a series of universal cancer only markers(UCOMs)have emerged as strong candidates for effective and accurate early detection of cancer.While the clinical value of current cancer biomarkers is diminished by low sensitivity and/or low specificity,the unique characteristics of UCOMs ensure clinically meaningful results.Validation of the clinical potential of UCOMs in lung,cervical,endometrial,and urothelial cancers further supports the application of UCOMs in multiple cancer types and various clinical scenarios.In fact,the applications of UCOMs are currently under active investigation with further evaluation in the early detection of cancer,auxiliary diagnosis,treatment efficacy,and recurrence monitoring.The molecular mechanisms by which UCOMs detect cancers are the next important topics to be investigated.The application of UCOMs in real-world scenarios also requires implementation and refinement.

关 键 词：Cancer detection cancer screening DNA methylation cancer epigenetics cancer biomarkers 

分 类 号：R730[医药卫生—肿瘤]